Table 1.
Baseline characteristics of diabetes patients at discharge of myocardial infarction
| Overall | No GLP-1 RA users | GLP-1 RA users | |
|---|---|---|---|
| Number of individuals | 17 868 | 17 503 | 365 |
| Age (years) | 71 [63, 79] | 71 [63, 79] | 65 [60, 71] |
| Age category (years) | |||
| <70 | 8152 (45.6) | 7903 (45.2) | 249 (68.2) |
| ≥70 | 9716 (54.4) | 9600 (54.8) | 116 (31.8) |
| Women | 6417 (35.9) | 6296 (36.0) | 121 (33.2) |
| Smoking | |||
| Never smoker | 6804 (38.1) | 6689 (38.2) | 115 (31.5) |
| Ex-smoker | 6370 (35.7) | 6195 (35.4) | 175 (47.9) |
| Current smoker | 3407 (19.1) | 3347 (19.1) | 60 (16.4) |
| Missing | 1287 (7.2) | 1272 (7.3) | 15 (4.1) |
| BMI (kg/m2) | 28.3 [25.3, 31.8] | 28.1 [25.3, 31.6] | 32.3 [29.4, 35.5] |
| BMI category (kg/m2) | |||
| <30 | 10 636 (59.5) | 10 531 (60.2) | 105 (28.8) |
| ≥30 | 6109 (34.2) | 5863 (33.5) | 246 (67.4) |
| Missing | 1123 (6.3) | 1109 (6.3) | 14 (3.8) |
| eGFR (mL/min/1.73 m2) | 75 [53, 91] | 75 [53, 91] | 80 [58, 96] |
| eGFR category (mL/min/1.73 m2) | |||
| <60 | 5544 (31.0) | 5445 (31.1) | 99 (27.1) |
| ≥60 | 11 722 (65.6) | 11 468 (65.5) | 254 (69.6) |
| Missing | 602 (3.4) | 590 (3.4) | 12 (3.3) |
| Comorbidities | |||
| STEMI | 5500 (30.8) | 5390 (30.8) | 110 (30.1) |
| Heart failure | 1613 (9.0) | 1583 (9.0) | 30 (8.2) |
| Cancer | 727 (4.1) | 715 (4.1) | 12 (3.3) |
| Hypertension | 13 570 (75.9) | 13 261 (75.8) | 309 (84.7) |
| PCI | 11 772 (65.9) | 11 503 (65.7) | 269 (73.7) |
| CABG | 2126 (11.9) | 2072 (11.8) | 54 (14.8) |
| Stroke | 2350 (13.2) | 2316 (13.2) | 34 (9.3) |
| PVD | 1148 (6.4) | 1131 (6.5) | 17 (4.7) |
| Atrial fibrillation | 2500 (14.0) | 2458 (14.0) | 42 (11.5) |
| Killip > 1 | 2321 (13.0) | 2289 (13.1) | 32 (8.8) |
| Medications | |||
| Aspirin | 16 216 (90.8) | 15 879 (90.7) | 337 (92.3) |
| Statins | 15 967 (89.4) | 15 625 (89.3) | 342 (93.7) |
| ACEi/ARBs | 10 331 (57.8) | 10 172 (58.1) | 159 (43.6) |
| Beta-blockers | 15 769 (88.3) | 15 445 (88.2) | 324 (88.8) |
| P2Y12 inhibitors | 13 239 (74.1) | 12 984 (74.2) | 255 (69.9) |
| Metformin | 9551 (53.5) | 9387 (53.6) | 164 (44.9) |
| Sulfonylurea | 2436 (13.6) | 2400 (13.7) | 36 (9.9) |
| DPP4i | 1056 (5.9) | 1041 (5.9) | 15 (4.1) |
| Insulin | 8350 (46.7) | 8173 (46.7) | 177 (48.5) |
ACEi, angiotensin-converting-enzyme inhibitor; ARBs, angiotensin receptor blockers; BMI, Body mass index; CABG, coronary artery bypass grafting; DPP4i, dipeptidyl peptidase 4 inhibitors; eGFR, estimated glomerular filtration rate; GLP-1 RA, GLP-1 receptor agonist; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST-segment elevation myocardial infarction.